Literature DB >> 2667764

Expression of the H-ras proto-oncogene is controlled by alternative splicing.

J B Cohen1, S D Broz, A D Levinson.   

Abstract

We previously demonstrated that a point mutation in the last intron of the human H-ras oncogene causes a significant increase in its expression and transforming efficiency. Here we establish the basis of this phenomenon. Using gene reconstruction experiments, we have identified a negative-acting element in the intron that is completely inactivated by the mutation. The effects of other nucleotide alterations introduced into this region suggested that the negative element might constitute an alternative exon. Transcripts containing this putative exon were identified and S1 nuclease analysis confirmed that the mutation prevents their synthesis. The abundance of these transcripts is low, apparently due to message instability and/or defective processing. The predicted product of the alternative transcript is suggested to lack transforming potential. Our findings demonstrate that alternative splicing normally operates to suppress p21H-ras expression and that this negative control is abolished by a variety of mutations that interfere with this process.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2667764     DOI: 10.1016/0092-8674(89)90427-3

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  35 in total

1.  Roles of hnRNP A1, SR proteins, and p68 helicase in c-H-ras alternative splicing regulation.

Authors:  Sònia Guil; Renata Gattoni; Montserrat Carrascal; Joaquín Abián; James Stévenin; Montse Bach-Elias
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

2.  Intron presence-absence polymorphism in Drosophila driven by positive Darwinian selection.

Authors:  Ana Llopart; Josep M Comeron; Frédéric G Brunet; Daniel Lachaise; Manyuan Long
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-11       Impact factor: 11.205

Review 3.  Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged.

Authors:  Charles J David; James L Manley
Journal:  Genes Dev       Date:  2010-11-01       Impact factor: 11.361

4.  Ovarian expression of cellular Ki-ras p21 varies with physiological status.

Authors:  S Palejwala; L T Goldsmith
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

5.  U1 small nuclear RNAs with altered specificity can be stably expressed in mammalian cells and promote permanent changes in pre-mRNA splicing.

Authors:  J B Cohen; S D Broz; A D Levinson
Journal:  Mol Cell Biol       Date:  1993-05       Impact factor: 4.272

6.  Base pairing at the 5' splice site with U1 small nuclear RNA promotes splicing of the upstream intron but may be dispensable for slicing of the downstream intron.

Authors:  D Y Hwang; J B Cohen
Journal:  Mol Cell Biol       Date:  1996-06       Impact factor: 4.272

7.  A splicing enhancer in the 3'-terminal c-H-ras exon influences mRNA abundance and transforming activity.

Authors:  D Y Hwang; J B Cohen
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

Review 8.  Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes.

Authors:  A Sveen; S Kilpinen; A Ruusulehto; R A Lothe; R I Skotheim
Journal:  Oncogene       Date:  2015-08-24       Impact factor: 9.867

9.  Splicing mutants and their second-site suppressors at the dihydrofolate reductase locus in Chinese hamster ovary cells.

Authors:  A M Carothers; G Urlaub; D Grunberger; L A Chasin
Journal:  Mol Cell Biol       Date:  1993-08       Impact factor: 4.272

10.  P19 H-ras induces G1/S phase delay maintaining cells in a reversible quiescence state.

Authors:  Maria Camats; Mariette Kokolo; Kate J Heesom; Michael Ladomery; Montse Bach-Elias
Journal:  PLoS One       Date:  2009-12-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.